HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trialYan Song, Jing Huang, Yunpeng Liu et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 20
Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patientsYiqun Li, Jing Huang, Yanfeng Wang et al.|Chinese Medical Journal|2022Cited by 6
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studyBo Zhang, Jing Huang, Yan Song et al.|Cell Reports Medicine|2023Cited by 6
Efficacy of HX008 in high microsatellite instability/mismatch repair–defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.Jing Huang, Shengmian Li, Yan Song et al.|Journal of Clinical Oncology|2021Cited by 5